Riskpilot← Back to searchSign inGet full accessAkloma BioScience Aktiebolag
ABActiveOrg 5566752928StockholmResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20050 employees
Revenue 2025
SEK 0
EBITDA margin
—
-524% vs 2024
Equity ratio
96.3%
Financial strength
Net profit 2025
SEK -1,6M
-409% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -1,1M | -524% |
| Net profit | SEK -1,6M | -409% |
| Total assets | SEK 3,7M | -35% |
| Equity | SEK 3,6M | -31% |
| Employees | 0 | — |
Legal name
Akloma BioScience Aktiebolag
Org number
5566752928
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
26 januari 2005
Share capital
SEK 135 640
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget ska bedriva forskning, utveckling, tillverkning och marknadsföring inom området för bioteknik och life sciences, äga och förvalta aktier och annan egendom med anknytning därtill samt driva annan därmed förenlig verksamhet.
Address
Stockholm
Phone
+468200015
Email
info@akloma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 70 | 0 | 0 |
| Staff expenses | — | — | — | — | −18 |
| EBITDA | −447 | −603 | −43 | −170 | −1 060 |
| Depreciation & amort. | −16 | −15 | −11 | −8 | −8 |
| EBIT | −463 | −618 | −54 | −178 | −1 068 |
| Net financials | −1 046 | −648 | −394 | −282 | −216 |
| Profit before tax | −986 | −942 | −251 | −319 | −1 623 |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | −986 | −942 | −251 | −319 | −1 623 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6 790 | 5 979 | 5 818 | 5 707 | 3 715 |
| Equity | 6 714 | 5 772 | 5 521 | 5 201 | 3 578 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 77 | 208 | 298 | 506 | 137 |
| Total debt | 77 | 208 | 298 | 506 | 137 |
EBITDA margin
-106037400.0%
This company
15.8%
Market median
-671122885% vs market
20212025
Equity ratio
96.3%
This company
38.2%
Market median
+152% vs market
20212025
Return on equity
-45.4%
This company
18.4%
Market median
-347% vs market
20212025
Net profit margin
-162336200.0%
This company
8.1%
Market median
-2004150717% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
LG Audit | Audit | 2021 – 2021 |
BM Chief Auditor | Chief Auditor | 2020 – 2021 |
RE Chief Auditor | Chief Auditor | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Akloma BioScience Aktiebolag 
Nessa Water ABBoard members of Akloma BioScience Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Gösta Ekeståhl | Audit | 0 companies |
| Bo Magnus Lagerberg | Chief Auditor | 0 companies |
| Robert Erik Viklund | Chief Auditor | 0 companies |
| Dan Ebbe Damm | Board of Directors | 0 companies |
| Erik Anders Magnus Nordkvist | Board of Directors | 0 companies |
| David Pursell | Board of Directors | 0 companies |
| Karl Axel Joachim Hjerpe | Chairman | 0 companies |